Evidence map›Paper›PMID 41234943›Full record

ArticleFrontiers in neurology2025

A multicenter, prospective cohort study on the anti-SARS-CoV-2 vaccination response in patients with multiple sclerosis in Germany.

Achim Berthele, Clemens Gödel, Boris-Alexander Kallmann, Markus Kowarik, Klaus Lehmann-Horn, Martin Marziniak, Sebastian Rauer, Veit Rothhammer, Florian Then Bergh, Mathias Wahl and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Achim BertheleDepartment of Neurology, School of Medicine and Health, Technical University Munich, München, Germany.
Clemens GödelDepartment of Neurology, Leipzig University, Leipzig, Germany.
Boris-Alexander KallmannMS Center Bamberg (mszb), Bamberg, Germany.
Markus KowarikDepartment of Neurology and Stroke, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Klaus Lehmann-HornNeuropraxis München Süd, Unterhaching, Germany.
Martin MarziniakDepartment of Neurology, kbo-Isar-Amper-Klinikum München-Ost, Haar, Germany.
Sebastian RauerDepartment of Neurology and Neuroscience, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, Freiburg, Germany.
Veit RothhammerDepartment of Neurology, University Hospital Erlangen, Erlangen, Germany.
Florian Then BerghDepartment of Neurology, Leipzig University, Leipzig, Germany.
Mathias WahlDepartment of Neurology, DKD Helios Klinik Wiesbaden, Wiesbaden, Germany.
Brigitte WildemannDepartment of Neurology, Molecular Neuroimmunology Group, University Hospital Heidelberg, Heidelberg, Germany.
Ksenija SchirduanBiogen GmbH, München, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This epidemiologic cohort study documented clinical and serological data in MS patients over several vaccination cycles against severe respiratory syndrome coronavirus-2 (SARS-CoV-2) in a real-world setting. Methods: Adult patients with MS were included during a period of 26 months from July 2021 if SARS-CoV-2 vaccination was planned, or first dose was given, or vaccination was completed within the last 6 weeks, or vaccination was completed >6 weeks ago and a booster dose was planned within the next 90 days. Humoral immune response to authorized SARS-CoV-2 vaccines was investigated during each vaccination cycle at baseline and approximately 1 and 6 months after vaccination. Immune response was defined as an anti-SARS-CoV-2 spike protein IgG titer >100 BAU/ml above pre-vaccination level and, separately, by the presence of SARS-CoV-2 neutralizing antibodies (NAb) approximately 1 month after the last vaccination. Results: Of 159 patients enrolled, 140 (88.1%) were being treated with a DMT. Most patients (67.9%, Conclusions: With the exception of anti-CD20 antibodies and S1PR modulators, DMTs did not impair humoral response to any of the authorized SARS-CoV-2 vaccines. Persistence of humoral immune response was seen over a period of at least 3 months in the majority of initial responders but was decreased in the anti-CD20 antibodies/S1PR modulator subgroup. Clinical trial registration: This epidemiological study is registered in the German Clinical Trials Register (DRKS00025893).

Indexed as

disease-modifying therapyimmune responsemultiple sclerosisSARS-CoV-2vaccination

Identifiers

PMID41234943
PMCPMC12606583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.